These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 10172049)

  • 1. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
    Barradell LB; Goa KL
    Pharmacoeconomics; 1995 Nov; 8(5):428-59. PubMed ID: 10172669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
    Lorenzoni R; Pagano D; Mazzotta G; Rosen SD; Fattore G; De Caterina R; Gensini G
    Eur Heart J; 1998 Oct; 19(10):1518-24. PubMed ID: 9820990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.
    Gillis JC; Goa KL
    Pharmacoeconomics; 1996 Sep; 10(3):281-310. PubMed ID: 10163575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
    Kalish SC; Gurwitz JH; Krumholz HM; Avorn J
    J Gen Intern Med; 1995 Jun; 10(6):321-30. PubMed ID: 7562123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The costs and benefits of community thrombolysis for acute myocardial infarction : a decision-analytic model.
    Vale L; Steffens H; Donaldson C
    Pharmacoeconomics; 2004; 22(14):943-54. PubMed ID: 15362930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and quality of life: thrombolysis and primary angioplasty.
    Goldman L
    J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):38S-41S. PubMed ID: 7775713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombolytic therapy in acute myocardial infarction.
    Paspa PA; Movahed A
    Am Fam Physician; 1992 Feb; 45(2):640-8. PubMed ID: 1739049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
    Goel V; Naylor CD
    Can J Cardiol; 1992; 8(1):31-8. PubMed ID: 1617509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours.
    Machecourt J; Dumoulin J; Calop J; Foroni L; Terisse MP; Henon T; Vanzetto G; Denis B; Bassand JP; Cassagnes J
    Eur Heart J; 1993 Jan; 14(1):75-83. PubMed ID: 8432296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits.
    Sherry S; Marder VJ
    J Am Coll Cardiol; 1991 Nov; 18(6):1579-82. PubMed ID: 1939964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction.
    Krumholz HM; Pasternak RC; Weinstein MC; Friesinger GC; Ridker PM; Tosteson AN; Goldman L
    N Engl J Med; 1992 Jul; 327(1):7-13. PubMed ID: 1598117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombolytic therapy in the elderly. Pharmacoeconomic considerations.
    Ramanathan K; Ellis CJ; White HD
    Drugs Aging; 1996 Apr; 8(4):237-44. PubMed ID: 8920173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
    Boland A; Dundar Y; Bagust A; Haycox A; Hill R; Mujica Mota R; Walley T; Dickson R
    Health Technol Assess; 2003; 7(15):1-136. PubMed ID: 12773258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.